Special Issue

Current Trends in RNA Virus Vaccines

Message from the Guest Editor

As you are perfectly aware, RNA viruses are one of the leading causes of infectious animal, human and zoonotic diseases worldwide, affecting millions of people, as clearly exemplified by the current devastating epidemic of the recently identified SARS-CoV-2 that has already infected more than 50 million people and caused more than 1.2 million deaths. Vaccine development has had an enormous impact on overcoming the global burden of diseases throughout the use of a vast number of classical and state of the art approaches, from purified inactivated and live attenuated viruses, to nucleic acid (DNA or RNA)-based candidates, virus-like particles, subunit elements, and recombinant viruses. However, licensed vaccines are only available for a few RNA viruses, and, thus, new and improved vaccines are necessary for many others. Therefore, to achieve a more comprehensive understanding of the current trends in vaccine development against RNA viruses, this Pharmaceuticals Special Issue is dedicated to recent developments and technological progress in vaccinology against RNA viruses, and the molecular mechanisms and immune responses involved.

Guest Editor

Prof. Dr. Juan Carlos Saiz

Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Madrid, Spain

Deadline for manuscript submissions

closed (15 April 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/70431

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

